- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00001347
Study of Usher Syndromes, Type 1 and Type 2
Usher Syndrome - Clinical and Molecular Studies
The purpose of this investigation is to gain additional knowledge about what causes type 1 and type 2 Usher syndrome-inherited diseases that can cause balance problems and impaired hearing and vision-and to develop better diagnostic tests. Patients with type 1 Usher syndrome usually are deaf from birth and have speech and balance problems. Patients with type 2 disease generally are hearing impaired but have no balance problems. All patients develop eye problems that cause difficulty seeing in the dark.
The development of newer and more sophisticated diagnostic tests may detect subtle differences in signs and symptoms that allow more accurate distinction between the two types of Usher syndrome. This study will use these tests to classify these syndromes and eventually identify the genes responsible for them.
Study participants will have a medical and family history taken and a family tree constructed. They will undergo a thorough eye examination, including special tests of color vision, field of vision, and ability to see in the dark. An electroretinogram will be done to measure the function of cells in the retina, and a procedure called fluorescein angiography will be done to look at and photograph the blood vessels in the retina. Special hearing and balance tests will also done. Hearing tests include physical examination of the ears and wearing earphones while listening to tones. Balance and coordination tests require tasks such as walking in a straight line and standing in the dark with eyes closed. A caloric stimulation test will also be done, in which a small amount of water is irrigated into the ear canal. For gene studies, blood samples will be collected from patients and all available family members.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The Usher Syndromes (USH), characterized by autosomal recessive inheritance, are genotypically distinct diseases which share specific phenotypic characteristics. Affected individuals have congenital neurosensory hearing impairment of variable severity and a progressive pigmentary retinal degeneration commonly referred to as retinitis pigmentosa. Interfamilial differences in USH patients are greater than intrafamilial differences and investigators have proposed at least two distinct phenotype types; Usher Syndrome type 1 (USH 1) and Usher Syndrome type 2 (USH 2) (Fishman 1983). Patients with USH 1 are profoundly deaf from birth, have unintelligible speech and absent vestibular function. Nightblindness is apparent in the 1st or 2nd decade accompanied by an extinguished electroretinogram (ERG) and profound loss of visual field. Patients with USH 2 can have moderate to severe hearing loss and normal vestibular function. Nightblindness occurs in the 2nd or 3rd decade, there is variable field loss and variable response by the ERG (Fishman 1983).
Heterogeneity has been verified by linkage studies and at least three USH 1 loci and two USH 2 loci are known (Kimberling et al 1990; Lewis et al 1990; Kaplan et al 1992; Smith et al 1992a.)
With increasingly sophisticated clinical testing, subtle differences may permit a more accurate distinction between the two USH phenotypes. The purpose of this study is to classify as accurately as possible these patients' clinical features by careful audiologic, vestibular, psychophysical and electrodiagnostic testing and correlate these with the genetic mutations identified through linkage studies and eventually to the genes (genetic mutations) as they become identified.
Studientyp
Einschreibung
Kontakte und Standorte
Studienorte
-
-
Maryland
-
Bethesda, Maryland, Vereinigte Staaten, 20892
- National Eye Institute (NEI)
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients must have documentation of neurosensory hearing loss and retinitis pigmentosa and fulfill the clinical characteristics (Table) as accepted for USH 1 and USH 2.
- The minimal test battery will identify all patients with USH 1 and USH 2 as well as possible subtypes.
- Candidates will be recruited from lists of patients willing to participate in research studies compiled by the R.P. Foundation, and by referral from their private physicians.
- On occasion additional family members will be studied after an initial individual is ascertained as above.
- No patients with intrauterine and childhood infections, and intrauterine and birth complications can result in trauma to both the auditory or visual system and a positive history for these conditions will necessitate exclusion from the study.
Studienplan
Wie ist die Studie aufgebaut?
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Lewis RA, Otterud B, Stauffer D, Lalouel JM, Leppert M. Mapping recessive ophthalmic diseases: linkage of the locus for Usher syndrome type II to a DNA marker on chromosome 1q. Genomics. 1990 Jun;7(2):250-6. doi: 10.1016/0888-7543(90)90547-8.
- Kimberling WJ, Moller CG, Davenport S, Priluck IA, Beighton PH, Greenberg J, Reardon W, Weston MD, Kenyon JB, Grunkemeyer JA, et al. Linkage of Usher syndrome type I gene (USH1B) to the long arm of chromosome 11. Genomics. 1992 Dec;14(4):988-94. doi: 10.1016/s0888-7543(05)80121-1.
- Smith RJ, Lee EC, Kimberling WJ, Daiger SP, Pelias MZ, Keats BJ, Jay M, Bird A, Reardon W, Guest M, et al. Localization of two genes for Usher syndrome type I to chromosome 11. Genomics. 1992 Dec;14(4):995-1002. doi: 10.1016/s0888-7543(05)80122-3.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Erkrankungen des Nervensystems
- Augenkrankheiten
- Neurologische Manifestationen
- Erkrankung
- Angeborene Anomalien
- Netzhautdegeneration
- Erkrankungen der Netzhaut
- Genetische Krankheiten, angeboren
- Otorhinolaryngologische Erkrankungen
- Ohrenkrankheiten
- Augenkrankheiten, erblich
- Netzhautdystrophien
- Empfindungsstörungen
- Anomalien, mehrere
- Hörstörungen
- Sehstörungen
- Taubblinde Störungen
- Hörverlust, sensorineural
- Blindheit
- Schwerhörigkeit
- Taubheit
- Syndrom
- Retinitis
- Retinitis pigmentosa
- Usher-Syndrome
Andere Studien-ID-Nummern
- 930161
- 93-EI-0161
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Retinitis pigmentosa
-
MeiraGTx UK II LtdSyne Qua Non Limited; Bionical EmasAbgeschlossenX-chromosomale Retinitis pigmentosaVereinigtes Königreich, Vereinigte Staaten
-
Oslo University HospitalRekrutierungRetinitis pigmentosa | Retinitis pigmentosa 11Norwegen
-
Jinnah Burn and Reconstructive Surgery Centre,...The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township... und andere MitarbeiterRekrutierungRetinitis pigmentosa (RP)Pakistan
-
AbbVieAktiv, nicht rekrutierendFortgeschrittene Retinitis pigmentosaVereinigte Staaten
-
jCyte, IncCalifornia Institute for Regenerative Medicine (CIRM)AbgeschlossenRetinitis pigmentosa (RP)Vereinigte Staaten
-
Janssen Research & Development, LLCJanssen Research & Development, LLCAktiv, nicht rekrutierendX-chromosomale Retinitis pigmentosaBelgien, Kanada, Vereinigte Staaten, Israel, Vereinigtes Königreich, Spanien, Dänemark, Frankreich, Italien, Niederlande, Schweiz
-
Janssen Research & Development, LLCAktiv, nicht rekrutierendX-chromosomale Retinitis pigmentosaVereinigte Staaten, Vereinigtes Königreich
-
GenSight BiologicsRekrutierungNicht-syndromale Retinitis pigmentosaVereinigte Staaten, Frankreich, Vereinigtes Königreich
-
Janssen Research & Development, LLCJanssen Research & Development, LLCAktiv, nicht rekrutierendX-chromosomale Retinitis pigmentosaVereinigte Staaten, Kanada, Israel, Vereinigtes Königreich, Spanien, Dänemark, Frankreich, Belgien, Italien, Niederlande, Schweiz
-
BiogenAbgeschlossenX-chromosomale Retinitis pigmentosaVereinigte Staaten, Vereinigtes Königreich